Skip to content

Study · Animal study (in vivo) · rat · 2002

20 results

Toxic effect of single treatment with bromantane on neurological status of experimental animals.

Iezhitsa IN, Spasov AA, Bugaeva LI, Morozov IS

Bulletin of experimental biology and medicine1 Apr 2002Cited by 1 (Europe PMC)

PMID12124651 (opens in a new tab)DOI10.1023/a:1016206306875 (opens in a new tab)PepBankPUB-12124651
Publisher pagePubMedAsk about this study
Jump to 20 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study20

20 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Safety outcome

    In rats, bromantane stimulated behavioral activity at lower doses.

    In plain wordsIn rats, lower bromantane doses stimulated behavioral activity.

    Peptide
    Bromantane
    Outcome
    IncreaseBehavioral activity at lower doses
    Study

    ratn: not reported in source

    rats
    Outcome group
    Locomotor and behavioral activity · Nervous system and cognition
    Studied dose
    30-300 mg/kgAs given in this study (rat).

    Source sentences

    Summary
    The drug in doses of 30-300 mg/kg stimulated and in doses of 600-9,600 mg/kg suppressed behavioral activity.
  2. 02AnimalAnimal study (in vivo)Safety outcome

    In rats, higher bromantane doses suppressed behavioral activity.

    In plain wordsIn rats, higher bromantane doses suppressed behavioral activity.

    Peptide
    Bromantane
    Outcome
    DecreaseBehavioral activity at higher doses
    Study

    ratn: not reported in source

    rats
    Outcome group
    Locomotor and behavioral activity · Nervous system and cognition
    Studied dose
    600-9,600 mg/kgAs given in this study (rat).

    Source sentences

    Summary
    The drug in doses of 30-300 mg/kg stimulated and in doses of 600-9,600 mg/kg suppressed behavioral activity.
  3. 03AnimalAnimal study (in vivo)Safety outcome

    In rats, single lower bromantane doses increased spontaneous motor activity.

    In plain wordsIn rats, single lower bromantane doses increased spontaneous movement.

    Peptide
    Bromantane
    Outcome
    IncreaseSpontaneous motor activity at lower doses
    Study

    ratn: not reported in source

    rats
    Outcome group
    Locomotor and behavioral activity · Nervous system and cognition
    Studied dose
    30-300 mg/kgAs given in this study (rat).

    Source sentences

    Summary
    Spontaneous motor activity increased after single treatment with bromantane in doses of 30-300 mg/kg, did not change after treatment in doses of 600 mg/kg, and was inhibited after treatment in doses above 600 mg/kg.
  4. 04AnimalAnimal study (in vivo)Safety outcome

    In rats, bromantane did not change spontaneous motor activity at the intermediate dose.

    In plain wordsIn rats, the intermediate bromantane dose did not change spontaneous movement.

    Peptide
    Bromantane
    Outcome
    No significant changeSpontaneous motor activity at intermediate dose
    Study

    ratn: not reported in source

    rats
    Outcome group
    Locomotor and behavioral activity · Nervous system and cognition
    Studied dose
    600 mg/kgAs given in this study (rat).

    Source sentences

    Summary
    Spontaneous motor activity increased after single treatment with bromantane in doses of 30-300 mg/kg, did not change after treatment in doses of 600 mg/kg, and was inhibited after treatment in doses above 600 mg/kg.
  5. 05AnimalAnimal study (in vivo)Safety outcome

    In rats, high bromantane doses inhibited spontaneous motor activity.

    In plain wordsIn rats, high bromantane doses inhibited spontaneous movement.

    Peptide
    Bromantane
    Outcome
    DecreaseSpontaneous motor activity at high doses
    Study

    ratn: not reported in source

    rats
    Outcome group
    Locomotor and behavioral activity · Nervous system and cognition
    Studied dose
    >600 mg/kgAs given in this study (rat).

    Source sentences

    Summary
    Spontaneous motor activity increased after single treatment with bromantane in doses of 30-300 mg/kg, did not change after treatment in doses of 600 mg/kg, and was inhibited after treatment in doses above 600 mg/kg.
  6. 06AnimalAnimal study (in vivo)Safety outcome

    In rats, intermediate bromantane doses reduced the pain sensitivity threshold.

    In plain wordsIn rats, intermediate bromantane doses lowered the pain threshold.

    Peptide
    Bromantane
    Outcome
    DecreasePain threshold at intermediate doses
    Study

    ratn: not reported in source

    rats
    Outcome group
    Locomotor and behavioral activity · Nervous system and cognition
    Studied dose
    300-600 mg/kgAs given in this study (rat).

    Source sentences

    Summary
    In doses of 300-600 mg/kg the drug reduced pain sensitivity threshold and in doses above 600 mg/kg elevated the pain threshold and tactile sensitivity and reaction to knock.
  7. 07AnimalAnimal study (in vivo)Safety outcome

    In rats, high bromantane doses elevated the pain threshold.

    In plain wordsIn rats, high bromantane doses raised the pain threshold.

    Peptide
    Bromantane
    Outcome
    IncreasePain threshold at high doses
    Study

    ratn: not reported in source

    rats
    Outcome group
    Locomotor and behavioral activity · Nervous system and cognition
    Studied dose
    >600 mg/kgAs given in this study (rat).

    Source sentences

    Summary
    In doses of 300-600 mg/kg the drug reduced pain sensitivity threshold and in doses above 600 mg/kg elevated the pain threshold and tactile sensitivity and reaction to knock.
  8. 08AnimalAnimal study (in vivo)Safety outcome

    In rats, high bromantane doses elevated tactile sensitivity.

    In plain wordsIn rats, high bromantane doses increased touch sensitivity.

    Peptide
    Bromantane
    Outcome
    IncreaseTactile sensitivity
    Study

    ratn: not reported in source

    rats
    Outcome group
    Locomotor and behavioral activity · Nervous system and cognition
    Studied dose
    >600 mg/kgAs given in this study (rat).

    Source sentences

    Summary
    In doses of 300-600 mg/kg the drug reduced pain sensitivity threshold and in doses above 600 mg/kg elevated the pain threshold and tactile sensitivity and reaction to knock.
  9. 09AnimalAnimal study (in vivo)Safety outcome

    In rats, high bromantane doses elevated reaction to knock.

    In plain wordsIn rats, high bromantane doses increased reaction to knock.

    Peptide
    Bromantane
    Outcome
    IncreaseReaction to knock
    Study

    ratn: not reported in source

    rats
    Outcome group
    Locomotor and behavioral activity · Nervous system and cognition
    Studied dose
    >600 mg/kgAs given in this study (rat).

    Source sentences

    Summary
    In doses of 300-600 mg/kg the drug reduced pain sensitivity threshold and in doses above 600 mg/kg elevated the pain threshold and tactile sensitivity and reaction to knock.
  10. 10AnimalAnimal study (in vivo)Safety outcome

    In rats, bromantane induced mydriasis at all studied doses.

    In plain wordsIn rats, bromantane dilated pupils at all studied doses.

    Peptide
    Bromantane
    Outcome
    IncreaseMydriasis
    Study

    ratn: not reported in source

    rats
    Outcome group
    Locomotor and behavioral activity · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Bromantane induced mydriasis in all studied doses; in doses above 10 g/kg the preparation induced blepharoptosis.
  11. 11AnimalAnimal study (in vivo)Safety outcome

    In rats, bromantane induced blepharoptosis at high doses.

    In plain wordsIn rats, high bromantane doses caused drooping eyelids.

    Peptide
    Bromantane
    Outcome
    IncreaseBlepharoptosis
    Study

    ratn: not reported in source

    rats
    Outcome group
    Locomotor and behavioral activity · Nervous system and cognition
    Studied dose
    >10 g/kgAs given in this study (rat).

    Source sentences

    Summary
    Bromantane induced mydriasis in all studied doses; in doses above 10 g/kg the preparation induced blepharoptosis.
  12. 12AnimalAnimal study (in vivo)Safety outcome

    In rats, high bromantane doses slightly increased respiration rate.

    In plain wordsIn rats, high bromantane doses slightly increased breathing rate.

    Peptide
    Bromantane
    Outcome
    IncreaseRespiration rate
    Study

    ratn: not reported in source

    rats
    Outcome group
    Respiratory function · Respiratory
    Studied dose
    >5 g/kgAs given in this study (rat).

    Source sentences

    Summary
    In doses above 5 g/kg bromantane slightly increased respiration rate and depth (Kussmaul-like respiration).
  13. 13AnimalAnimal study (in vivo)Safety outcome

    In rats, high bromantane doses slightly increased respiration depth.

    In plain wordsIn rats, high bromantane doses slightly increased breathing depth.

    Peptide
    Bromantane
    Outcome
    IncreaseRespiration depth
    Study

    ratn: not reported in source

    rats
    Outcome group
    Respiratory function · Respiratory
    Studied dose
    >5 g/kgAs given in this study (rat).

    Source sentences

    Summary
    In doses above 5 g/kg bromantane slightly increased respiration rate and depth (Kussmaul-like respiration).
  14. 14AnimalAnimal study (in vivo)Safety outcome

    In some rats, high bromantane doses induced regurgitation.

    In plain wordsIn some rats, high bromantane doses caused regurgitation.

    Peptide
    Bromantane
    Outcome
    Not applicableRegurgitation
    Study

    ratn: not reported in source

    rats
    Outcome group
    Adverse events · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In some animals bromantane in high doses induced regurgitation, diarrhea, and polyuria.
  15. 15AnimalAnimal study (in vivo)Safety outcome

    In some rats, high bromantane doses induced diarrhea.

    In plain wordsIn some rats, high bromantane doses caused diarrhea.

    Peptide
    Bromantane
    Outcome
    Not applicableDiarrhea
    Study

    ratn: not reported in source

    rats
    Outcome group
    Adverse events · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In some animals bromantane in high doses induced regurgitation, diarrhea, and polyuria.
  16. 16AnimalAnimal study (in vivo)Safety outcome

    In some rats, high bromantane doses induced polyuria.

    In plain wordsIn some rats, high bromantane doses caused excessive urination.

    Peptide
    Bromantane
    Outcome
    Not applicablePolyuria
    Study

    ratn: not reported in source

    rats
    Outcome group
    Adverse events · Kidney and urinary
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In some animals bromantane in high doses induced regurgitation, diarrhea, and polyuria.
  17. 17AnimalAnimal study (in vivo)Safety outcome

    In rats, rectal temperature decreased after virtually all bromantane doses.

    In plain wordsIn rats, rectal temperature decreased after virtually all bromantane doses.

    Peptide
    Bromantane
    Outcome
    DecreaseRectal temperature
    Study

    ratn: not reported in source

    rats
    Outcome group
    Body temperature · Whole body
    Studied dose
    Dose not stated

    Measurements

    Temperature decrease
    0.5 to 1 degrees C
    virtually all doses

    Source sentences

    Summary
    Rectal temperature decreased by 0.5-1 degrees C after virtually all doses.
  18. 18AnimalAnimal study (in vivo)Mechanism

    In rats, bromantane behavioral effects were associated with stimulation of central dopamine structures.

    In plain wordsIn rats, bromantane behavioral effects were linked to stimulation of central dopamine structures.

    Peptide
    Bromantane
    Outcome
    IncreaseCentral dopamine structures
    Study

    ratn: not reported in source

    rats
    Outcome group
    Locomotor and behavioral activity · Nervous system and cognition
    Studied dose
    30 and 600 mg/kgAs given in this study (rat).

    Source sentences

    Summary
    Behavioral effects of bromantane in doses of 30 and 600 mg/kg were associated with stimulation of the central dopamine and suppression of muscarinic and nicotinic cholinergic structures, n-cholinolytic effects of bromantane was more pronounced at a dose of 30 mg/kg than at a dose of 600 mg/kg.
  19. 19AnimalAnimal study (in vivo)Mechanism

    In rats, bromantane behavioral effects were associated with suppression of muscarinic cholinergic structures.

    In plain wordsIn rats, bromantane behavioral effects were linked to suppression of muscarinic cholinergic structures.

    Peptide
    Bromantane
    Outcome
    DecreaseMuscarinic cholinergic structures
    Study

    ratn: not reported in source

    rats
    Outcome group
    Locomotor and behavioral activity · Nervous system and cognition
    Studied dose
    30 and 600 mg/kgAs given in this study (rat).

    Source sentences

    Summary
    Behavioral effects of bromantane in doses of 30 and 600 mg/kg were associated with stimulation of the central dopamine and suppression of muscarinic and nicotinic cholinergic structures, n-cholinolytic effects of bromantane was more pronounced at a dose of 30 mg/kg than at a dose of 600 mg/kg.
  20. 20AnimalAnimal study (in vivo)Mechanism

    In rats, bromantane suppressed nicotinic cholinergic structures, with stronger n-cholinolytic effects at 30 than 600 mg/kg.

    In plain wordsIn rats, bromantane suppressed nicotinic cholinergic structures more strongly at 30 than 600 mg/kg.

    Peptide
    Bromantane
    Outcome
    DecreaseNicotinic cholinergic structures
    Study

    ratn: not reported in source

    rats
    Outcome group
    Locomotor and behavioral activity · Nervous system and cognition
    Studied dose
    30 and 600 mg/kgAs given in this study (rat).

    Source sentences

    Summary
    Behavioral effects of bromantane in doses of 30 and 600 mg/kg were associated with stimulation of the central dopamine and suppression of muscarinic and nicotinic cholinergic structures, n-cholinolytic effects of bromantane was more pronounced at a dose of 30 mg/kg than at a dose of 600 mg/kg.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 12:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.